Generate Biomedicines, Inc. (GENB)
$0.00-$0.09 (-0.53%) Latest sessionExtended Hours
Noubar AfeyanNoubar AfeyanGenerate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
https://www.generatebiomedicines.comSEC filings for GENB on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 1,000 | $16K |
16 Form 4 filings on record, the earliest from Mar 2, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Frances Arnold - Director | Open-market sale | Common Stock | 1,000 | $16.00 | $16K | |
| Michael Nally - Officer | Open-market purchase | Common Stock | 20,000 | $12.00 | $240K | |
| Rupert Vessey | Grant or award | Stock Option (Right to Buy) | 29,561 | $0.00 | - | |
| Beth Grous - Officer | Open-market purchase | Common Stock | 300 | $16.00 | $5K | |
| Beth Grous - Officer | Grant or award | Stock Option (Right to Buy) | 114,020 | $0.00 | - | |
| Frances Arnold | Grant or award | Stock Option (Right to Buy) | 29,561 | $0.00 | - | |
| Laurie Anne Lee - Officer | Grant or award | Stock Option (Right to Buy) | 42,230 | $0.00 | - | |
| Sean Martin - Officer | Grant or award | Stock Option (Right to Buy) | 190,034 | $0.00 | - | |
| Nancy A. Simonian | Grant or award | Stock Option (Right to Buy) | 29,561 | $0.00 | - | |
| Jason Silvers - Officer | Open-market purchase | Common Stock | 500 | $16.00 | $8K | |
| Jason Silvers - Officer | Open-market purchase | Common Stock | 500 | $16.00 | $8K | |
| Jason Silvers - Officer | Open-market purchase | Common Stock | 1,000 | $16.00 | $16K | |
| Jason Silvers - Officer | Grant or award | Stock Option (Right to Buy) | 295,608 | $0.00 | - | |
| Jason Silvers - Officer | Grant or award | Stock Option (Right to Buy) | 274,493 | $0.00 | - | |
| Noubar Afeyan | Grant or award | Stock Option (Right to Buy) | 29,561 | $0.00 | - | |
| Noubar Afeyan | Other | Series A Preferred Stock | 18,483,785 | $0.00 | - | |
| Noubar Afeyan | Other | Common Stock | 12,723,940 | - | - | |
| Noubar Afeyan | Other | Common Stock | 13,702,224 | - | - | |
| Noubar Afeyan | Other | Common Stock | 987,491 | - | - | |
| Noubar Afeyan | Other | Common Stock | 2,777,752 | - | - | |
| Noubar Afeyan | Other | Common Stock | 2,777,752 | - | - | |
| Noubar Afeyan | Open-market purchase | Common Stock | 1,562,500 | $16.00 | $25.00M | |
| Noubar Afeyan | Open-market purchase | Common Stock | 1,562,500 | $16.00 | $25.00M | |
| Noubar Afeyan | Open-market purchase | Common Stock | 1,562,500 | $16.00 | $25.00M | |
| Noubar Afeyan | Other | Series A Preferred Stock | 17,016,215 | $0.00 | - | |
| Noubar Afeyan | Other | Series A Preferred Stock | 1,500,000 | $0.00 | - | |
| Noubar Afeyan | Other | Series B Preferred Stock | 843,881 | $0.00 | - | |
| Noubar Afeyan | Other | Series B Preferred Stock | 1,265,822 | $0.00 | - | |
| Noubar Afeyan | Other | Series B Preferred Stock | 2,953,586 | $0.00 | - | |
| Noubar Afeyan | Other | Series B Preferred Stock | 2,109,704 | $0.00 | - | |
| Noubar Afeyan | Other | Series C Preferred Stock | 2,531,644 | $0.00 | - | |
| Noubar Afeyan | Other | Series C Preferred Stock | 1,265,822 | $0.00 | - | |
| Noubar Afeyan | Other | Series C Preferred Stock | 2,109,704 | $0.00 | - | |
| Gevorg Grigoryan - Officer | Grant or award | Stock Option (Right to Buy) | 295,608 | $0.00 | - | |
| Gevorg Grigoryan - Officer | Grant or award | Stock Option (Right to Buy) | 196,368 | $0.00 | - | |
| Michael Nally - Officer | Other | Common Stock | 658,327 | - | - | |
| Michael Nally - Officer | Grant or award | Stock Option (Right to Buy) | 844,595 | $0.00 | - | |
| Michael Nally - Officer | Grant or award | Stock Option (Right to Buy) | 844,595 | $0.00 | - | |
| Michael Nally - Officer | Other | Series A Preferred Stock | 1,000,000 | $0.00 | - | |
| Stephane Bancel | Other | Common Stock | 724,160 | - | - | |
| Stephane Bancel | Grant or award | Stock Option (Right to Buy) | 29,561 | $0.00 | - | |
| Stephane Bancel | Other | Series A Preferred Stock | 1,100,000 | $0.00 | - | |
| Jane L. Mendillo | Open-market purchase | Common Stock | 1,500 | $16.00 | $24K | |
| Jane L. Mendillo | Grant or award | Stock Option (Right to Buy) | 29,561 | $0.00 | - | |
 Marsha Fanucci | Grant or award | Stock Option (Right to Buy) | 29,561 | $0.00 | - | |
| Paul Gray Parker | Grant or award | Stock Option (Right to Buy) | 29,561 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| ARNOLD FRANCES | Director | 32,210 | $521K | View on EDGAR | |
| ARNOLD FRANCES | Director | 1,000 | $16K | View on EDGAR |
Generate Biomedicines, Inc. (GENB) had 1 insider filing in the last 90 days, with the most recent on 2026-09-03. The full record for GENB runs to 16 Form 4 filings, the earliest from 2026-03-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of GENB were filed in the last 90 days. 9 purchases are on record for this company.
1 insider sale of GENB was filed in the last 90 days, totaling $16K.
This page tracks GENB Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add GENB to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
